ASCO 2021 Kidney Cancer - Results from #20

Viewing 21-40 of 48 articles

ASCO 2021: Association Between Neutrophil-to-Eosinophil Ratio (NER) and Efficacy Outcomes in the JAVELIN Renal 101 Study

ASCO 2021: PROSPER: Phase III RandOmized Study Comparing PERioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy

ASCO 2021: Pembrolizumab plus Axitinib Versus Sunitinib as First-Line Therapy for Advanced Clear Cell Renal Cell Carcinoma: Results from 42-Month Follow-up of KEYNOTE-426

ASCO 2021: Health-Related Quality-of-Life Analysis from the Phase 3 CLEAR Trial of Lenvatinib + Pembrolizumab or Everolimus Versus Sunitinib for Patients with Advanced RCC

ASCO 2021: Phase 2 Study of Belzutifan (MK-6482), an Oral Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor, for Von Hippel-Lindau (VHL) Disease-Associated Clear Cell Renal Cell Carcinoma (ccRCC)

ASCO 2021: A Quantum Leap in Cancer Adjuvant Immunotherapy - KEYNOTE 564 Phase 3 Trial - Discussion

ASCO 2021: CANTATA: Primary Analysis of a Global, Randomized, Placebo-Controlled, Double-Blind Trial of Telaglenastat + Cabozantinib Versus Placebo + Cabozantinib in mRCC Patients Who Progressed on Immune Checkpoint Inhibitor or Anti-Angiogenic Therapies

ASCO 2021: Expanding VEGF Blockade Combination Therapeutic Options in Advanced Renal Cell Carcinoma: Discussion

ASCO 2021: Results from the KEYNOTE-564 Study of Adjuvant Pembrolizumab in Resected Clear-Cell Renal Cell Carcinoma (RCC)

ASCO 2021: Pembrolizumab Versus Placebo as Post-Nephrectomy Adjuvant Therapy for Patients with Renal Cell Carcinoma: Randomized, Double-Blind, Phase III KEYNOTE-564 Study

ASCO 2021: TIVO-3: Durability of Response and Updated Overall Survival of Tivozanib Versus Sorafenib in Metastatic Renal Cell Carcinoma

ASCO 2021: Nivolumab Plus Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma: Results of a Phase 2 Trial

ASCO 2021: Cabozantinib Exposure-Response Analysis for the Phase 3 CheckMate 9ER Trial of Nivolumab Plus Cabozantinib Versus Sunitinib in First-Line Advanced Renal Cell Carcinoma

ASCO 2021: A Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Advanced Renal Cell Carcinoma With Bone Metastases (RADICAL/Alliance A031801)

ASCO 2021: Unanswered Questions in the Management of Advanced Renal Cell Carcinoma

ASCO 2021: Survival Benefit of Nephrectomy Prior to Immunotherapy-Based Combinations in Patients with Metastatic Renal Cell Carcinoma: An FDA Pooled Analysis

ASCO 2021: Temporal Characteristics of Treatment-Emergent Adverse Events and Dose Modifications with Tivozanib and Sorafenib in the Phase 3 TIVO-3 Study of Relapsed or Refractory mRCC

ASCO 2021: Safety and Efficacy Outcomes with Nivolumab plus Ipilimumab in Patients with Advanced Renal Cell Carcinoma and Brain Metastases: Results from the CheckMate 920 Trial

ASCO 2021: Phase II Study of Nivolumab and Salvage Nivolumab + Ipilimumab in Treatment-Naïve Patients (Pts) with Advanced Non-Clear Cell Renal Cell Carcinoma (nccRCC) (HCRN GU16-260-Cohort B)

ASCO 2021: Efficacy of Nivolumab/Ipilimumab in Patients with Initial or Late Progression with Nivolumab: Updated Analysis of a Tailored Approach in Advanced Renal Cell Carcinoma (TITAN-RCC)

1
2
3